A Phase Ii Trial Of Atezolizumab (Anti-Pd-L1) With Carboplatin In Patients With Metastatic Triple-Negative Breast Cancer (Mtnbc).

Eric Michael Lander,Brian David Lehmann,Payal D Shah,Elizabeth Claire Dees,Tarah Jean Ballinger,Paula Raffin Pohlmann,Cesar Augusto Santa-Maria,Yu Shyr,Ingrid A. Mayer,Ben Ho Park,Jennifer A. Pietenpol,Vandana G Abramson

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 2|浏览45

暂无评分

摘要

TPS1112Background: Patients with metastatic triple negative breast cancer (mTNBC) have limited treatment options. Recent studies with a PD-L1 inhibitor and taxane based chemotherapy have demonstrat...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要